Please login to the form below
drug pricing
This page shows the latest drug pricing news and features for those working in and with pharma, biotech and healthcare.
Moderna looks to price COVID-19 vaccine at $50-$60 per course
Shines spotlight on pricing strategies for potential vaccines. COVID-19 vaccine frontrunner Moderna is allegedly looking to price its candidate at around $50-$60 per course, according to a report from ... According to the report, Moderna’s proposed
Latest news
-
Lilly joins new Medicare scheme to reduce insulin prices
of-pocket drug costs.
-
FDA clears generic of Daraprim, the ‘poster drug’ for price-gouging
Phoenixus has resisted pressure to lower the price of the drug, and is reportedly haemorrhaging cash – a situation which will presumably only get worse once the generic is available. ... Gaming tactics include preventing generic drugmakers getting
-
Ex-Sandoz exec admits role in generic drug price-fixing plot
The two named products are clobetasol, an eczema and psoriasis treatment, and nystatin triamcinolone, an anti-fungal drug that also has a corticosteroid. ... Drug pricing is a particularly hot-topic among US politicians at the moment, and has snowballed
-
Presidential hopeful Bernie Sanders criticises BioMarin’s gene therapy price
GENEr8-1 trial of the drug – enough to meet the pre-specified criteria for regulatory review. ... The uncertainty of the durability of BioMarin’s drug has left space for other haemophilia A hopefuls from rival developers.
-
US start-up EQRx promises approach that will slash drug prices
Plans to have its first drug on the market in just five years. ... costs. “The time is now for a market-based solution to rising drug costs,” says Borisy.
More from news
Approximately 71 fully matching, plus 197 partially matching documents found.
Latest Intelligence
-
The impact of COVID-19 on clinical trials
Based on our discussions with venture capitalists, many anticipate potentially severe cash flow issues for drug developers. ... The impact of the pandemic on clinical trials is likely to be felt on a policy level, including in drug pricing negotiations.
-
Health trust in a COVID-19 world – a unique opportunity for pharma
Our team there hypothesised that this may be due to several highly publicised issues including Servier’s long-awaited trial over the safety of a weight loss drug, a large, monthslong ... hospital strike, increasing anti-vaccination sentiment and
-
Risks, reforms and rewards: the evolving Russian healthcare market
However, efforts to increase state control of drug pricing and pressure to manufacture medicines locally could prove a challenge for international drug companies.
-
The changing nature of approvals – what does the future hold?
Deal- making has impacted R&D and when considered together with drug pricing pressures, these trends raise the question of pharmaceutical company sustainability. ... first launched on the world drug market than major companies (those with R&D spend of
-
Assessing the risks in annuity pricing models
The challenge of adapting pricing models to accommodate new therapies. By Walter Colasante. ... Understanding annuity payment models. On a very fundamental level, annuity pricing models are structured to reimburse drug manufacturers in instalments and
More from intelligence
Approximately 7 fully matching, plus 37 partially matching documents found.
Latest appointments
-
New faces at Lucid Group and ZPB Associates
Most recently, she worked in the consultancy’s rare diseases division, where is provided crisis management support in pricing/access barriers for an orphan drug.
-
Pfizer’s Emms takes up ABPI presidency
Emms is no stranger to these issues, having served on the ABPI board and taken part in the negotiations over the future of drug pricing in the UK. ... He has not been afraid to criticise the outcomes of these discussions too, saying in November that the
-
Bayer's Martin Hesse moves to Daiichi Sankyo Europe
Commenting on the environment in which he starts at Daiichi, Hesse said securing the company's profitability and competitiveness in the light of drug pricing interventions will a major challenge.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Last chance to register - Webinar: How to price a pharmaceutical product during a global economic recession
A panel of experts in pricing, chaired by our Senior Executive Advisor, Raf De Wilde, will discuss how best to navigate these pricing challenges and make sure you achieve the optimal ... Jaime Espin Former Member of the WHO Guideline Panel on Country
-
How to weather the pricing competiton
Over the years, the threat of pricing competition has increasingly become a concern. ... For the drug Saizen, Merck Serono was able to move out of tenders and into contracts.
-
Enabling market access through outcomes-based pricing
Furthermore, in disease areas where drug competition is high, the evidence gathered via outcomes-based pricing agreements can be used to drive market access by differentiating from competitor products, and targeting ... Staton, T. (2016). Most US payers
-
Pricing and Market Access Simulator
Reliable tool for value assessment of pipeline products. YOUR CHALLENGE:. PRICING A PRODUCT EARLY IN DEVELOPMENT. ... The pricing and market access simulator app offers you a unique opportunity to take early investment decisions more robustly than ever:.
-
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. ... Keeping reimbursement goals achievable. Pricing drugs and gaining reimbursement can be a real challenge for drug developers.
More from PMHub
Approximately 8 fully matching, plus 8 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- Positive COPD data for Synairgen's SNG001 supports COVID-19 programme
- Roche’s Ocrevus boasts positive long-term data in MS
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
PMHub
Merrill Brink International
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
